We live in a world where only 1 in 2 people have reliable access to the insulin they need. Over the past four years, the ACCISS Study has looked at access issues from multiple perspectives to gain a comprehensive understanding of the insulin landscape and factors impacting access. Through this ongoing research, we have gathered non-biased evidence and developed useful evidence-based tools to help decision-makers and others at both the global and national levels. Our objective is to increase access to affordable, quality-assured insulin for everyone who needs it.
There is no ‘one-size-fits-all’ approach to insulin treatment. However, the lack of access and affordability affects people living with diabetes the world over. The ACCISS Study continues to identify access barriers to both human and analogue insulin and is working to ensure affordability for both users and national health systems.
Further, we recognise that that while insulin is essential, it is not the only element required for successful diabetes treatment – access to supplies, diagnostic and monitoring tools, care and support are also critical. Our work will help governments and other stakeholders to ensure access to affordable quality-assured insulin, appropriate diabetes treatment and care those in need.